MorphoSys Announces Clinical Milestone in Blood Disorders Program
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Clinical Milestone in Blood Disorders Program
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that it has received a milestone payment from Novartis in connection with
the initiation of a Phase 1 clinical trial of a HuCAL antibody in the field of
blood disorders. This becomes the eleventh therapeutic antibody made using
MorphoSys's technologies that Novartis is evaluating in clinical trials. The
associated milestone payment was booked in Q2 2015.
"With eleven therapeutic antibody programs in clinical development to date, our
alliance with Novartis has resulted in a substantial drug candidate portfolio,"
commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today's
news represents the second clinical milestone with our partners during the
course of this year."
MorphoSys's collaboration with Novartis has resulted in eleven clinical programs
to date, six of which are in Phase 1 development, with another four programs in
Phase 2 and one in Phase 3. In total, MorphoSys's proprietary and partnered
clinical pipeline currently comprises 24 unique antibody molecules, which are
being evaluated in more than 50 clinical trials.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 90 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Mario Brkulj
Associate Director Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Jessica Rush
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1940533/700820.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1940533]
Unternehmensinformation / Kurzprofil:
Datum: 23.07.2015 - 07:30 Uhr
Sprache: Deutsch
News-ID 408611
Anzahl Zeichen: 4681
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 196 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Clinical Milestone in Blood Disorders Program"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
